Suboptimal Response to Biologics in Severe Asthma—A Marker of Humoral Immunodeficiencies
-
Published:2024-07
Issue:7
Volume:12
Page:1840-1849.e3
-
ISSN:2213-2198
-
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
-
language:en
-
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice
Author:
Tiotiu AngelicaORCID,
De Meulder Bertrand,
Vaillant Pierre,
Mouton-Faivre Claudie,
Jaussaud Roland
Reference38 articles.
1. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry;Canonica;World Allergy Organ J,2019
2. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis;Akenroye;J Allergy Clin Immunol,2022
3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines—recommendations on the use of biologicals in severe asthma;Agache;Allergy,2020
4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines—recommendations on the use of biologicals in severe asthma;Agache;Allergy,2020
5. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis;Edris;Respir Res,2019